G. Pairaudeau

发表

An analysis of the attrition of drug candidates from four major pharmaceutical companies

R. M. Owen, A. Leach, P. Leeson, 2015, Nature Reviews Drug Discovery.

Creativity, innovation and lean sigma: a controversial combination?

Garry Pairaudeau, G. Pairaudeau, Jonas A Pettersson, 2011, Drug discovery today.

From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.

G. Pairaudeau, A. Bailey, E. Cadogan, 2012, Bioorganic & medicinal chemistry letters.

Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists.

G. Pairaudeau, A. Bailey, E. Cadogan, 2011, Bioorganic & medicinal chemistry letters.

Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists.

G. Pairaudeau, A. Bailey, E. Cadogan, 2011, Bioorganic & medicinal chemistry letters.

QSAR and the rational design of long-acting dual D2-receptor/beta 2-adrenoceptor agonists.

R. Austin, P. Barton, A. Davis, 2003, Journal of medicinal chemistry.

A genetically selected cyclic peptide inhibitor of BCL6 homodimerization.

M. Waring, G. Pairaudeau, A. Tavassoli, 2018, Bioorganic & medicinal chemistry.

AZD3199: A potent and selective β2-adrenergic receptor agonist with rapid onset of action

R. Austin, G. Pairaudeau, D. Nicholls, 2011, ATS 2011.

The In Vivo Profile Of AZD3199: A Novel, Fast Acting B2-Agonist With A Long Duration Of Action

G. Pairaudeau, D. Nicholls, S. Connolly, 2011, ATS 2011.

From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.

P. Leeson, B. Springthorpe, P. Barton, 2007, Bioorganic & medicinal chemistry letters.

Towards a hit for every target

G. Pairaudeau, W. Janzen, K. Birmingham, 2016, Nature Reviews Drug Discovery.

Collaborative virtual screening to elaborate an imidazo[1,2-a]pyridine hit series for visceral leishmaniasis†

O. Engkvist, G. Pairaudeau, H. Nakai, 2020, RSC medicinal chemistry.

Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.

G. Pairaudeau, A. Bailey, E. Cadogan, 2014, ACS medicinal chemistry letters.

The discovery of new spirocyclic muscarinic M3 antagonists.

Daniel J. Warner, G. Pairaudeau, A. Bailey, 2010, Bioorganic & medicinal chemistry letters.

Switching between agonists and antagonists at CRTh2 in a series of highly potent and selective biaryl phenoxyacetic acids.

A. Davis, G. Pairaudeau, S. Thom, 2011, Bioorganic & medicinal chemistry letters.

One-Pot Four-Component Reaction for the Generation of Pyrazoles and Pyrimidines

G. Pairaudeau, D. Chekmarev, Michael J. Stocks, 2008 .

Synthesis applications of cationic aza-Cope rearrangements. 26. Enantioselective total synthesis of (-)-strychnine

L. Overman, G. Pairaudeau, S. Knight, 1993 .

Synthesis of functionalised cyclopentenones via rearrangement of pyranones

G. Pairaudeau, S. Caddick, S. Khan, 2000 .

A novel synthetic approach to the cardiotoxin Batrachotoxin: An efficient synthesis of the AB ring system

M. Drew, G. Pairaudeau, P. Parsons, 1993 .

Chemistry of allene sulphoxides: a new methodology for the synthesis of spiroketals and 1,5-dioxadecalin ring systems

J. M. Underwood, G. Pairaudeau, P. Parsons, 1987 .

Stereoselective synthesis of polyfunctionalised hydroxylated cyclopentanes from dihydroxylated 2-cyclopentenone derivatives

G. Pairaudeau, S. Caddick, P. Hitchcock, 2001 .

ASYMMETRIC TOTAL SYNTHESES OF (-)- AND (+)-STRYCHNINE AND THE WIELAND-GUMLICH ALDEHYDE

L. Overman, G. Pairaudeau, S. Knight, 1995 .

High fidelity Suzuki-Miyaura coupling for the synthesis of DNA encoded libraries enabled by micelle forming surfactants.

M. Waring, G. Pairaudeau, A. Madin, 2019, Bioconjugate chemistry.

Studies Toward the Synthesis of Natural and Unnatural Dienediynes. Part 2: A Practical Approach to Functionalised Cyclopentenones

G. Pairaudeau, S. Caddick, N. Smith, 2000 .

Potent Reversible Inhibition of Myeloperoxidase by Aromatic Hydroxamates*

G. Pairaudeau, J. Unitt, A. Kettle, 2013, The Journal of Biological Chemistry.

The Discovery of MMP7 Inhibitors Exploiting a Novel Selectivity Trigger

Anu J. Tervo, G. Pairaudeau, A. Ward, 2011, ChemMedChem.

Inhibition of low-density lipoprotein receptor degradation with a cyclic peptide that disrupts the homodimerization of IDOL E3 ubiquitin ligase† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8sc01186a

G. Pairaudeau, E. Valeur, P. Wan, 2018, Chemical science.

The Royal Society of-density lipoprotein receptor degradation with a cyclic peptide that disrupts the homodimerization of IDOL E 3 ubiquitin ligase †

G. Pairaudeau, E. Valeur, P. Wan, 2018 .

Identification of Small-Molecule Positive Modulators of Calcitonin-like Receptor-Based Receptors.

G. Pairaudeau, C. Reynolds, A. Pioszak, 2020, ACS pharmacology & translational science.

IMI European Lead Factory — democratizing access to high-throughput screening

Stuart P. McElroy, Philip S. Jones, H. V. van Vlijmen, 2021, Nature reviews. Drug discovery.

Collaborative Virtual Screening Identifies a 2-Aryl-4-aminoquinazoline Series with Efficacy in an In Vivo Model of Trypanosoma cruzi Infection

O. Engkvist, G. Pairaudeau, David Shum, 2023, Journal of medicinal chemistry.

A Practical Method for Targeted Library Design Balancing Lead‐like Properties with Diversity

Garry Pairaudeau, Michael J Stocks, Gareth R H Wilden, 2009, ChemMedChem.

The convergence of artificial intelligence and chemistry for improved drug discovery.

O. Engkvist, G. Pairaudeau, Clive P Green, 2018, Future medicinal chemistry.

The enantiomer of strychnine is a weak antagonist of the inhibitory glycine receptor

R. Miledi, L. Overman, Q. Nguyen, 1995 .

Functional Group Tolerance of a Micellar on-DNA Suzuki-Miyaura Cross-Coupling Reaction for DNA-Encoded Library Design.

G. Pairaudeau, Marco Potowski, A. Brunschweiger, 2021, The Journal of organic chemistry.